In today’s briefing:
- Ohayo Japan | Dovish Fed Speak
- Australia Banks – Negative Loan Growth Reaches August 2021 Levels
- Shroom Shmooz – Spotlight on Psilocybin
Ohayo Japan | Dovish Fed Speak
- Tech-Driven gains pushed the S&P 500 up by 0.74%, while the Nasdaq Composite hit a record high, surging 1.68%
- Japanese Prime Minister Fumio Kishida addressed U.S. legislators, emphasizing Japan’s readiness to share the responsibility of upholding the international order
- Fujifilm Holdings plans to invest $4.5 billion by 2028 to expand its biopharmaceutical contract manufacturing business
Australia Banks – Negative Loan Growth Reaches August 2021 Levels
- Australia domestic credit growth is now at -2.2% YoY in January 2024, the worst figure since August 2021.
- There are negative implications for the delta of net interest income for Australia’s banks as loan growth moves negative.
- Risk of rising credit costs is higher, not only from worsening insolvencies with corporates, but also with rising mortgage bad loans.
Shroom Shmooz – Spotlight on Psilocybin
- From ancient rituals to modern medicine. Psilocybin is a natural psychedelic compound contained in more than 200 species of (magic) mushrooms that grow in diverse natural environments worldwide, from humid tropical forests to grassy meadows to urban green spaces.
- Psilocybin has a long history of use in religious rituals and divinatory ceremonies of indigenous cultures going back millennia, but in more modern times has attracted a growing interest from modern medicine for its potential therapeutic effects on the neural pathways.
The properties of psilocybin and its active form psilocin closely resemble serotonin.